Drug: |
CB-839 + Talazoparib |
|||
---|---|---|---|---|
Trial: |
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors |
|||
Conditions: | Solid Tumors | |||
Trial Status: |
Terminated |
Columbia University - Herbert Irving Cancer Center |
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.